Feature

Posted by Repositive, December 2018

Repositive Makes the News: Autumn 2018 Headline Round-Up

Limited time offer: free Personal Shopper Service

At the start of October we launched our Personal Shopper Service, free of charge for a limited time only. From 1 October to 31 December, commercial scientists working in translational oncology can ask us to conduct a free of charge, tailored, confidential search for specific cancer models they are struggling to find. If the model can’t be found, we will endeavour to find within our growing Translational Oncology Network a Contract Research Organisation willing to develop the specific model needed! It has been fantastic to see such a buzz about the service, with the campaign launch featuring in the news around the globe. Read more about the service in Pharma IQ, Bio IT World or Scientist Live.

Fiona and Repositive reap rewards during award season

Congratulations to our Founder and CEO, Fiona, who, at the end of October, was named on the 2018 WISE100 list - the first ever index to recognise inspiring and influential women in social enterprise, impact investment and social innovation. Now in its second year, WISE100 is organised by the NatWest SE100 Index in partnership with Pioneers Post. As a first-time entrepreneur, Fiona received recognition for founding Repositive in 2014 as a social enterprise before rapidly growing the organisation by raising venture capital investment from notable investors like Amadeus Capital, Ananda Social Venture Fund and super-angel Jonathan Milner, as well as successfully obtaining early and on-going support and collaboration from key biopharma and biotech partners including AstraZeneca, Boehringer Ingelheim, XenTech and Shanghai LIDE Biotech.

In the same week as she was named on the WISE100 list, Fiona was once again recognised for her leadership at Repositive, as she was Highly Commended in the CEO of the Year category at Cambridge Independent’s Science and Technology Awards. In just its second year the judging panel had a tough time selecting winners because of the “phenomenal” standard locally, and receiving her award Fiona was quick to thank to the whole team at Repositive for being awesome!

To round off the season of awards, Repositive triumphed at the European Super Angels Club (ESAC) ‘Digital Health Stars 2018’ awards. Having won a national pitching event in the UK in the autumn to earn a place in the final round, Fiona travelled to Vienna to compete against five finalists from across Europe. After pitching and fielding questions from the jury and the audience, Fiona secured Repositive’s position as ESAC Digital Health Champion 2018!

Focus on data

As our followers will already know, advancements in cancer research are being hampered by issues of data sharing, security and ownership – both ethical and commercial.

There is more genomic data available than ever before, with as many as one in 25 individuals in the US thought to have undertaken genetic tests while in the UK, Genomics England and the NHS announced recently that they have now sequenced 100,000 genomes. This upward trend in genetic testing has led to more frequent discussions, both in the UK and the US, about how safe it is to test, hold, and share genetic information. Fiona shared her thoughts on the benefits and risks to sharing genetic data in an article for Front Line Genomics, which you can read here.

The Repositive team also works to promote ethical and efficient data sharing practices, to encourage data managers to ensure data is Findable, Accessible, Interoperable, and Reusable (FAIR). But this is not as straightforward as it sounds, because there is no industry standard for data providers and brokers to follow. The team authored the FAIR Guide for Data Providers to Maximize Sharing of Human Genomic Data to support willing data providers and data brokers in ensuring their data is FAIR, and Fiona recently shared some of the highlights of this guidance in a recent article published on the Technology Networks website.

If you want to keep up to date with our news why not subscribe to our mailing list or follow us on Twitter or LinkedIn?

Posted by
Repositive

Repositive

Repositive Press Team
See all Repositive's posts